Toxoplasmosis, a zoonotic protozoal disease, belongs to the group of TORCH infections caused by the intracellular parasite Toxoplasma gondii, which in the case of a manifestation is characterized by a polymorphism of clinical manifestations with a predominant lesion of the nervous, lymphatic systems, eyes, skeletal muscles and myocardium.
Patients with latent HT do not need specific antiprotozoal treatment. Conventional therapy of concomitant diseases, dispensary observation activities are conducted.
Treatment in the period of exacerbation of chronic toxoplasmosis should be complex. Prolonged antiprotozoal therapy is pathogenetically unfounded. Toxoplasmosis is treated with a combination of pyrimethamine and sulfadiazine. Both drugs can cross the blood-brain barrier.
Treatment of toxoplasmosis in the period of exacerbation should be complex. Prolonged antiprotozoal therapy is pathogenetically unjustified. Treatment of co-morbidities, sanation of foci of chronic infections that adversely affect the state of the immune system, it is desirable to conduct before the appointment of antiprotozoal drugs.